Login to Your Account

Astrazeneca sews up global Daliresp rights in $575M Takeda respiratory deal

By Marie Powers
News Editor

Wednesday, December 16, 2015

Astrazeneca plc expanded its reach in the global respiratory market with a $575 million deal to acquire the core respiratory assets of Takeda Pharmaceutical Co. Ltd. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription